44.1751.60% ( +0.695 )
Trading: Oct 22, 15:59:39 (EDT)Current ValuationThe current P/E ratio is 110.31, above the reasonable range, cheaper than 5.11% of the time in the past 3 years, and the industry ranks 64/605, the industry Median -1.93.
110.31xP/E
$43.48Stock price
$0.39Earnings per share
110.31xP/E
Stock price$43.48Earnings per share$0.39
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 14.81x
- Typical range
- 13.14x–21.27x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0285684112
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
PTGXUSProtagonist Therap | 107.77x | 326.72% | $8.93B |
ALKSUSAlkermes | 110.31x | 136.87% | $7.29B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
